RichardAnthonyWalgrenMDPhD
Oncology • Indianapolis, INHematologic Oncology
VP, Global Patient Safety Medical and Safety Science
Dr. Walgren is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Lilly Corporate Ctr
Indianapolis, IN 46285Phone+1 317-433-0801
Education & Training
Washington University/B-JH/SLCH ConsortiumFellowship, Hematology and Medical Oncology, 2004 - 2008- Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 2002 - 2004
Medical University of South CarolinaClass of 2002
St. Louis College of PharmacyBS Pharm, Pharmacy, Cum Laude, 1989 - 1994
Certifications & Licensure
IN State Medical License 2008 - 2025
SC State Medical License 1995 - 2001
IL State Medical License 1994 - 2000
Publications & Presentations
PubMed
- Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial.Nirav N Shah, Michael Wang, Lindsey E Roeker, Krish Patel, Jennifer A Woyach
Haematologica. 2024-10-03 - 13 citationsPirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma.Michael L Wang, Wojciech Jurczak, Pier Luigi Zinzani, Toby A Eyre, Chan Y Cheah
Journal of Clinical Oncology. 2023-08-20 - 7 citationsClinical outcomes among patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who received treatment with a covalent BTK and BCL2 inhibitor...Toby A Eyre, Lisa M Hess, Tomoko Sugihara, Dan He, Manoj Khanal
Leukemia & Lymphoma. 2023-05-01
Professional Memberships
- Member
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
